PAREXEL WINS CLINICAL RESEARCH TEAM OF THE YEAR SCRIP AWARD
Boston, MA, November 15, 2010 — PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that the Company has won the 2010 Scrip Award for “Clinical Research Team of the Year.” The award was presented to PAREXEL at the sixth annual Scrip Awards ceremony, hosted by Scrip Intelligence, a leading news, data, and information service for the global pharmaceutical industry, on November 4, 2010 in London, England. The annual Scrip Awards, which are independently judged by a panel of senior industry experts, honor contributions to the advancement of science and improvement of healthcare worldwide. The panel of judges chose PAREXEL as the winner of the Clinical Research Team of the Year Award over the research teams of other clinical research organization (CRO) nominees, as well as in-house research teams from pharmaceutical companies.
According to Philip Jarvis, Publisher of Scrip Intelligence, “The Scrip Award for Clinical Research Team of the Year honors the achievement of the team that has made the most difference to a pharmaceutical or biotechnology company’s research program. The Scrip Award recognizes the PAREXEL team’s outstanding work in performing a great task, given the drug, target population, and number of centers and countries involved—ultimately assisting the sponsor in securing a patent extension and extending access of an important proprietary product. The judges were particularly impressed with the clinical research team’s ability to rapidly complete study start-up and implement the required timelines. The PAREXEL team demonstrated excellence not only in managing a complex global trial, but also in driving greater efficiencies through best practices and innovation as part of a wider strategic partnership.”
“PAREXEL is honored to receive the Clinical Research Team of the Year Award, and have our achievements recognized by the judges of the Scrip Awards,” said Josef von Rickenbach, Chairman and Chief Executive Officer of PAREXEL International. “This recognition reflects our continued commitment to clients to deliver high levels of quality and best-practice outsourcing approaches focused on significant value creation. We are pleased that the judges recognized this team’s performance in the context of a strategic partnership that leveraged a new operational model to improve effectiveness and accelerate development.”
PAREXEL continues to be a premier, trusted partner to clients who rely on the Company for expertise and flexibility as well as the efficiencies of a worldwide infrastructure, to help them more quickly achieve their goals. PAREXEL complements client organizations with strategic insight, in-depth scientific knowledge, tactical expertise, and a wealth of experience throughout the product development process, including worldwide regulatory expertise, Phase I-IV clinical research services, eClinical technologies that accelerate development, and medical communications services, as well as reimbursement and market access services. PAREXEL is focused on providing tailored solutions that match a client’s specific needs by applying the right blend of resources and capabilities, as well as the right guidance and high level of quality, needed to help clients bring safe and effective treatments to patients sooner.
# # #
About PAREXEL International
PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 54 countries around the world, and has approximately 10,170 employees. For more information about PAREXEL International visit www.PAREXEL.com.
This release contains “forward-looking” statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “will,” “would,” “could,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company’s actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings, the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company’s dependence on certain industries and clients; the Company’s ability to win new business, manage growth and costs, and attract and retain employees; the Company’s ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company’s business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2010 as filed with the SEC on November 9, 2010, which “Risk Factors” discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.